Pardanani et al. screened 200 patients with either chronic or blast-phase MPN for IDH mutations and detected a total of nine patients bearing IDH mutations (five IDH1 mutations and four IDH2 mutations): The cumulative IDH mutational frequency was about 4% for patients in chronic phase and 21% for blast-phase MPN [68]. This evidence concerns the gene IDH2 and myeloproliferative neoplasm.